NKTR vs. AVIR, OMER, MCRB, ADCT, ASMB, PYXS, XERS, INZY, XBIT, and NBTX
Should you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include Atea Pharmaceuticals (AVIR), Omeros (OMER), Seres Therapeutics (MCRB), ADC Therapeutics (ADCT), Assembly Biosciences (ASMB), Pyxis Oncology (PYXS), Xeris Biopharma (XERS), Inozyme Pharma (INZY), XBiotech (XBIT), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical preparations" industry.
Nektar Therapeutics (NASDAQ:NKTR) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
Nektar Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500.
Nektar Therapeutics received 610 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 70.61% of users gave Nektar Therapeutics an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
In the previous week, Nektar Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Nektar Therapeutics and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.54 beat Nektar Therapeutics' score of -0.20 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.
Nektar Therapeutics currently has a consensus target price of $3.50, suggesting a potential upside of 165.15%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Nektar Therapeutics is more favorable than Atea Pharmaceuticals.
75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 3.1% of Nektar Therapeutics shares are owned by insiders. Comparatively, 14.5% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Atea Pharmaceuticals has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -306.31%. Atea Pharmaceuticals' return on equity of -23.07% beat Nektar Therapeutics' return on equity.
Atea Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Nektar Therapeutics beats Atea Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Nektar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nektar Therapeutics Competitors List
Related Companies and Tools
